Project description
Cancer biomarkers for predicting treatment outcome
Drug effectiveness is often hampered by systemic cytotoxicity. Anti-cancer drugs exhibit adverse effects by damaging normal tissues and organs. Prodrugs that can be activated by specific stimuli to exert their pharmacological effect have emerged as safer options. CP-506 is such a prodrug that is activated by the low oxygen levels of tumours (hypoxia) known to promote cancer aggressiveness and therapy resistance. CP-506 causes DNA damage so tumours defective in DNA repair pathways are at a disadvantage. The mission of the ERC-funded ReverseTheAdvantage project is to develop a solution that can identify tumours that exhibit both hypoxia and defects in DNA damage repair to predict the efficacy of CP-506 treatment.
Fields of science
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Funding Scheme
HORIZON-AG-LS - HORIZON Lump Sum Grant
Coordinator
6200 MD Maastricht
Netherlands
See on map